Twitxy
Saved
@alexdrilon's profile picture
View on X

Alexander Drilon MD

@alexdrilon

Chief, Early Drug Development Service; Associate Attending Physician, Thoracic Oncology Service; Memorial Sloan Kettering Cancer Center
New York mskcc.org/cancer-care/do… Joined October 2011
213 Following 4.4K Followers 172 Posts

Latest posts 5

Alexander Drilon MD @alexdrilon
In the era of Project Optimus, expeditiousness needs to be preserved for dose finding in rare cancers. Common cancers now contain multiple rare genomic and proteomic subsets, underscoring the importance of this mindset. @YoninaMG @AlexiaIasonos
Elizabeth McKenna @ElizSMcKenna Jun 3, 2024
Now online in @CD_AACR, a special commentary for #ASCO24: Optimus-Era Dose Finding for Rare Cancers - by @YoninaMG, Sean Devlin, @AlexiaIasonos, and @alexdrilon doi.org/10.1158/2159-8… @MSKCancerCenter
View quoted post on X
3 replies 2 reposts 25 likes 5.2K views View on X
Alexander Drilon MD @alexdrilon
Repotrectinib is FDA approved for ROS1+ lung cancers in the TKI naive and pretreated settings. Many thanks to the patients, advocates, and study teams around the world who made this possible. onclive.com/view/fda-appro…
www.onclive.com FDA Approves Repotrectinib for Locally Advanced or Metastatic ROS1+ NSCLC | OncLive The FDA has approved repotrectinib (Augtyro) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.
1 replies 31 reposts 105 likes 17K views View on X
Alexander Drilon MD @alexdrilon
Don’t miss out on the opportunity to join the lab of the fabulous Dr. Misale. Our phase I team is absolutely excited to continue working with her. Congratulations @Sandra_Misale!!
Sandra Misale @Sandra_Misale Jun 10, 2023
I have some news, I'm thrilled to announce that the Misale Lab will open in July at @hopkinskimmel @HopkinsMedicine! We will work on resistance to therapy in solid tumors and we are hiring. Join us in this journey! #newPI #LabLaunch #cancer #kras #targetedtherapies #WomenInSTEM
View quoted post on X
Alexander Drilon MD @alexdrilon
Breaking tradition can improve patient outcomes. In novel-known combinations where the novel drug is unlikely to work well alone, prolonged exposure to monotherapy in dose escalation is not patient-centric. This alternative FDA-approved phase I design poses a potential solution.
Cancer Discovery @CD_AACR Jun 3, 2023
Just published: #SHP2 Inhibition Sensitizes Diverse Oncogene-addicted Solid Tumors to Re-treatment with Targeted Therapy by @alexdrilon S. Michael Rothenberg and colleagues @MSKCancerCenter @PfizerOncMed. bit.ly/45HB06K #ASCO23
View quoted post on X
0 replies 16 reposts 44 likes 8.3K views View on X